The American College of Physicians endorses the necessity of a comprehensive process for disclosure of potential conflicts of interest to ensure the integrity of clinical guidelines and guidance statements.
A number of upward epidemiologic trends and associated risk factors for mortality seen in patients with diabetes.
In patients with prior myocardial infarction (MI)/ischemic stroke, treatment with alirocumab is associated with a reduction in low-density lipoprotein cholesterol (LDL-C), as well as reductions in lipoprotein(a), apolipoprotein B, and non-high-density lipoprotein cholesterol (non-HDL-C), according to study results published in the Journal of Clinical Lipidology. In addition, efficacy and safety results were similar in patients…
The American Heart Association and Heart Failure Society released a joint scientific statement summarizing the effects of type 2 diabetes management on heart failure outcomes.
A low-density lipoprotein-cholesterol level >4.9 mmol/L in addition to the Dutch Lipid Clinic Network Criteria score may help identify probable/definite or possible familial hypercholesterolemia.
Persistent high residual inflammatory risk is associated with an increased major adverse cardiac and cerebrovascular accident risk in patients undergoing percutaneous coronary intervention who have a low baseline low-density lipoprotein level.
Investigators substantiated strategies to encourage approval rates for proprotein convertase subtilisin/kexin type 9 inhibitors.
Objective short sleep duration is associated with daytime sleepiness, whereas obstructive sleep apnea is associated with obesity, dyslipidemia, and hypertension.
Researchers conducted a phishing simulation and observed the vulnerability of healthcare employees to potential cybersecurity attacks.
There is a high prevalence of discordance in the reduction of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) in response to evolocumab treatment.
